NCT04629729 2025-12-11FT819 in Subjects With B-cell MalignanciesFate TherapeuticsPhase 1 Active not recruiting54 enrolled
NCT03677596 2023-11-22A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible PatientsPfizerPhase 4 Completed102 enrolled 27 charts
NCT01786135 2017-10-19A Safety Study of SGN-CD19A for B-Cell LymphomaSeagen Inc.Phase 1 Completed64 enrolled
NCT01786096 2017-07-02A Safety Study of SGN-CD19A for Leukemia and LymphomaSeagen Inc.Phase 1 Completed92 enrolled